TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exploratory/Proof of Principle Microbiota Study
Brief Summary: This clinical trial will evaluate the stool of infants fed one of two infant formulas, which contain different types of proteins, or breast milk to determine if different proteins have an effect on the type of bacteria that enters and lives in an infant's intestine early in life.


Options:
A: Arm Label: Amix; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Amix | Intervention Type: DIETARY_SUPPLEMENT; Name: Amix; Assigned to Arm(s): Amix
B: Arm Label: Glutamine; Type: EXPERIMENTAL; Interventions: Drug: Glutamine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Glutamine; Assigned to Arm(s): Glutamine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Amino acid based infant formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Amino acid based infant formula | Arm Label: Extensively hydrolyzed casein infant formula; Type: EXPERIMENTAL; Interventions: Other: Extensively hydrolyzed casein infant formula | Arm Label: Mother's own breast milk; Type: OTHER; Interventions: Other: Mother's own breast milk | Intervention Type: OTHER; Name: Amino acid based infant formula; Assigned to Arm(s): Amino acid based infant formula | Intervention Type: OTHER; Name: Extensively hydrolyzed casein infant formula; Assigned to Arm(s): Extensively hydrolyzed casein infant formula | Intervention Type: OTHER; Name: Mother's own breast milk; Assigned to Arm(s): Mother's own breast milk
D: Arm Label: Amino Acid Formula; Type: EXPERIMENTAL; Interventions: Other: Amino Acid Formula | Arm Label: Amino Acid commercial formula; Type: ACTIVE_COMPARATOR; Interventions: Other: Amino Acid formula | Intervention Type: OTHER; Name: Amino Acid Formula; Assigned to Arm(s): Amino Acid Formula | Intervention Type: OTHER; Name: Amino Acid formula; Assigned to Arm(s): Amino Acid commercial formula

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, 24-Week Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Reslizumab Subcutaneous Dosing (110 mg Every 4 Weeks) in Patients With Oral Corticosteroid Dependent Asthma and Elevated Blood Eosinophils
Brief Summary: The primary objective of the study is to determine the ability of reslizumab administered by subcutaneous injection to produce a corticosteroid-sparing effect in patients with oral corticosteroid (OCS)-dependent asthma and elevated blood eosinophils, without loss of asthma control.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: omalizumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: omalizumab; Assigned to Arm(s): Omalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Reslizumab 3.0 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 3.0 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Reslizumab 110 mg; Type: EXPERIMENTAL; Interventions: Drug: Reslizumab, Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication, Drug: Oral Corticosteroid (OCS) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Non-Oral Corticosteroid (non-OCS) Asthma Medication, Drug: Oral Corticosteroid (OCS) | Intervention Type: DRUG; Name: Reslizumab; Assigned to Arm(s): Reslizumab 110 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Non-Oral Corticosteroid (non-OCS) Asthma Medication; Assigned to Arm(s): Placebo, Reslizumab 110 mg | Intervention Type: DRUG; Name: Oral Corticosteroid (OCS); Assigned to Arm(s): Placebo, Reslizumab 110 mg

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: ACTION PAC: Adolescents Committed to Improvement of Nutrition & Physical Activity
Brief Summary: Using a previously created weight management program for adolescents, the intervention will be implemented through school-based health centers (SBHC) and will be delivered by SBHC providers trained in Motivational Interviewing. Students at intervention school sites will be compared to students at control school sites. All students will have baseline, 1 year, and 2 year follow-up to assess if students in the intervention school sites will have improved risk factor profile for metabolic syndrome, improved nutrition and increased physical activity when compared with students at control school sites.


Options:
A: Arm Label: The Health Lifestyles Interventions; Type: EXPERIMENTAL; Interventions: Behavioral: The Health Lifestyles Interventions | Arm Label: Receive no intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The Health Lifestyles Interventions; Assigned to Arm(s): The Health Lifestyles Interventions
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: Experimental | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Experimental; Assigned to Arm(s): 1
C: Arm Label: ACTION PAC Behavioral Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: ACTION PAC, Behavioral: Communication with parents | Arm Label: Comparison; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Communication with parents | Intervention Type: BEHAVIORAL; Name: ACTION PAC; Assigned to Arm(s): ACTION PAC Behavioral Intervention | Intervention Type: BEHAVIORAL; Name: Communication with parents; Assigned to Arm(s): ACTION PAC Behavioral Intervention, Comparison
D: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: Improve access to the school breakfast program | Arm Label: Comparison arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Improve access to the school breakfast program; Assigned to Arm(s): Intervention arm

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine if a program of physical activity, nutritional supplements and relaxation techniques is effective at decreasing post operative complications in frail colorectal cancer patients undergoing resection.


Options:
A: Arm Label: Pre-surgery physiotherapy; Type: OTHER; Interventions: Other: Pre-surgery physiotherapy | Arm Label: Waiting-list; Type: OTHER; Interventions: Other: Waiting-list | Intervention Type: OTHER; Name: Pre-surgery physiotherapy; Assigned to Arm(s): Pre-surgery physiotherapy | Intervention Type: OTHER; Name: Waiting-list; Assigned to Arm(s): Waiting-list
B: Arm Label: Prehabilitation Plus; Type: ACTIVE_COMPARATOR; Interventions: Other: Prehabilitation Plus | Arm Label: Rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Prehabilitation Plus; Assigned to Arm(s): Prehabilitation Plus
C: Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): N/A
D: Arm Label: Prehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Arm Label: Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Intervention Type: BEHAVIORAL; Name: Physical Exercise Program; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: DIETARY_SUPPLEMENT; Name: Whey Protein Isolate Powder; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: BEHAVIORAL; Name: Relaxation Techniques; Assigned to Arm(s): Prehabilitation, Rehabilitation

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: The purpose of this study is to determine if a program of physical activity, nutritional supplements and relaxation techniques is effective at decreasing post operative complications in frail colorectal cancer patients undergoing resection.


Options:
A: Arm Label: Prehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Arm Label: Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Physical Exercise Program, Dietary Supplement: Whey Protein Isolate Powder, Behavioral: Relaxation Techniques | Intervention Type: BEHAVIORAL; Name: Physical Exercise Program; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: DIETARY_SUPPLEMENT; Name: Whey Protein Isolate Powder; Assigned to Arm(s): Prehabilitation, Rehabilitation | Intervention Type: BEHAVIORAL; Name: Relaxation Techniques; Assigned to Arm(s): Prehabilitation, Rehabilitation
B: Arm Label: Prehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prehabilitation | Arm Label: No-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): Prehabilitation
C: Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): N/A
D: Arm Label: Pre and postoperative exercise; Type: EXPERIMENTAL; Interventions: Other: Physical activity | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Physical activity; Assigned to Arm(s): Pre and postoperative exercise

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Safety, Tolerability and Activity of BIVV009 in Healthy Volunteers and Patients With Complement-mediated Disorders. A Single/Multiple Ascending Dose Phase 1 Study.
Brief Summary: Prospective, double-blind, randomized, placebo-controlled First-In-Human study with four sub-parts: Part A, a single ascending dose study (SAD) in normal human volunteers (NHVs), Part B, a multiple ascending dose study (MAD) in NHVs, Part C, a multiple dose (MD) study in patients with a complement-mediated disorder, and Part E, a multiple dose (MD) study in patients with cold agglutinin disease previously treated with BIVV009 within the scope of a BIVV009 clinical trial or named patient program use. Note: For parts A-C as well as at the start of part E, study drug was named TNT009. The study drug name is changed to BIVV009 with final version Final 15.0 of the clinical study protocol.


Options:
A: Arm Label: Part A; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIV009, Other: Placebo | Arm Label: Part B; Type: PLACEBO_COMPARATOR; Interventions: Drug: BIV009, Other: Placebo | Arm Label: Part C; Type: EXPERIMENTAL; Interventions: Drug: BIV009 | Arm Label: Part E; Type: EXPERIMENTAL; Interventions: Drug: BIV009 | Intervention Type: DRUG; Name: BIV009; Assigned to Arm(s): Part A, Part B, Part C, Part E | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Part A, Part B
B: Intervention Type: DRUG; Name: Azathioprine or Mycophenolate mofetil; Assigned to Arm(s): N/A
C: Arm Label: Treatment Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Treatment Rituximab
D: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Corticotherapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: General Corticotherapy | Intervention Type: DRUG; Name: General Corticotherapy; Assigned to Arm(s): Corticotherapy | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Different Arachidonic Acid Supplementation on Psychomotor Development in Very Preterm Infants, a Randomized Controlled Trial
Brief Summary: Long-chain polyunsaturated fatty acids (LCPUFAs), arachidonic acid (AA omega-6; 20:4ω-6), and docosahexaenoic acid (DHA omega-3; 22:6ω-3), are required for the formation of non-myelinated cell membranes in the central nervous system, including in the retina, hence the great importance of them for appropriate visual and cognitive development.

In this study, the investigators assessed anthropometric, visual, auditory, and psychomotor development in very preterm infants who had diets supplemented with different LCPUFA amount of AA to support the importance of sufficient AA values in formula.


Options:
A: Arm Label: EN only; Type: EXPERIMENTAL; Interventions: Other: Withholding PN during the first week of ICU stay | Arm Label: EN plus early PN; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E | Intervention Type: OTHER; Name: Withholding PN during the first week of ICU stay; Assigned to Arm(s): EN only | Intervention Type: DRUG; Name: Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E; Assigned to Arm(s): EN plus early PN
B: Arm Label: Early parenteral nutrition; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Late parenteral nutrition; Type: EXPERIMENTAL; Interventions: Other: Late parenteral nutrition | Intervention Type: OTHER; Name: Late parenteral nutrition; Assigned to Arm(s): Late parenteral nutrition
C: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia) | Arm Label: B; Type: EXPERIMENTAL; Interventions: Drug: intensive insulin therapy (Actrapid IV to normoglycemia) | Intervention Type: DRUG; Name: intensive insulin therapy (Actrapid IV to normoglycemia); Assigned to Arm(s): B | Intervention Type: DRUG; Name: conventional insulin therapy (Actrapid IV only for excessive hyperglycemia); Assigned to Arm(s): A
D: Arm Label: Group A; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Preterm infants formula A | Arm Label: Group B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Preterm infants formula B | Intervention Type: DIETARY_SUPPLEMENT; Name: Preterm infants formula A; Assigned to Arm(s): Group A | Intervention Type: DIETARY_SUPPLEMENT; Name: Preterm infants formula B; Assigned to Arm(s): Group B

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Controlled, Open-label, 2-arm Parallel Group, Single Center Study to Demonstrate Reductions in Exposure to Selected Smoke Constituents in Healthy Smokers Switching to the Carbon Heated Tobacco Product 1.0 (CHTP 1.0) Compared to Continuing to Use Conventional Cigarettes During 5 Days in Confinement.
Brief Summary: The overall goal of the study is to demonstrate the reduction of biomarkers of exposure (BoExp) to selected harmful and potentially harmful constituents (HPHCs) in adult smokers switching for 5 days from conventional cigarette (CC) to Carbon Heated Tobacco Product 1.0 (CHTP 1.0) as compared to smokers continuing to use CC.


Options:
A: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG
B: Arm Label: CHTP 1.0; Type: EXPERIMENTAL; Interventions: Other: CHTP 1.0 | Arm Label: Conventional cigarette (CC); Type: ACTIVE_COMPARATOR; Interventions: Other: Conventional Cigarette (CC) | Intervention Type: OTHER; Name: CHTP 1.0; Assigned to Arm(s): CHTP 1.0 | Intervention Type: OTHER; Name: Conventional Cigarette (CC); Assigned to Arm(s): Conventional cigarette (CC)
C: Arm Label: Tobacco-Heating Cigarette; Type: EXPERIMENTAL; Interventions: Other: Tobacco-Heating Cigarette | Arm Label: Snus (Smokeless Tobacco); Type: EXPERIMENTAL; Interventions: Other: Snus (Smokeless Tobacco) | Arm Label: Tobacco-Burning Cigarette; Type: EXPERIMENTAL; Interventions: Other: Tobacco-Burning Cigarette | Intervention Type: OTHER; Name: Tobacco-Heating Cigarette; Assigned to Arm(s): Tobacco-Heating Cigarette | Intervention Type: OTHER; Name: Snus (Smokeless Tobacco); Assigned to Arm(s): Snus (Smokeless Tobacco) | Intervention Type: OTHER; Name: Tobacco-Burning Cigarette; Assigned to Arm(s): Tobacco-Burning Cigarette
D: Arm Label: THS 2.2 Menthol (mTHS 2.2); Type: EXPERIMENTAL; Interventions: Other: THS 2.2 Menthol (mTHS 2.2) | Arm Label: Menthol Conventional Cigarette (mCC); Type: ACTIVE_COMPARATOR; Interventions: Other: Menthol Conventional Cigarette (mCC) | Arm Label: Smoking abstinence (SA); Type: SHAM_COMPARATOR; Interventions: Other: Smoking Abstinence (SA) | Intervention Type: OTHER; Name: THS 2.2 Menthol (mTHS 2.2); Assigned to Arm(s): THS 2.2 Menthol (mTHS 2.2) | Intervention Type: OTHER; Name: Menthol Conventional Cigarette (mCC); Assigned to Arm(s): Menthol Conventional Cigarette (mCC) | Intervention Type: OTHER; Name: Smoking Abstinence (SA); Assigned to Arm(s): Smoking abstinence (SA)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Multicenter, Randomized, Single-Masked, Sham-Controlled Study of Safety, Tolerability and Evidence of Activity of Intravitreal APL-2 Therapy in Patients With Geographic Atrophy (GA)
Brief Summary: The primary objectives of the study are to assess the safety, tolerability and evidence of activity of multiple intravitreal (IVT) injections of pegcetacoplan in subjects with Geographic Atrophy associated with Age-Related Macular Degeneration (AMD).


Options:
A: Arm Label: FCFD4514S; Type: EXPERIMENTAL; Interventions: Drug: FCFD4514S | Arm Label: sham; Type: SHAM_COMPARATOR; Interventions: Drug: sham | Intervention Type: DRUG; Name: FCFD4514S; Assigned to Arm(s): FCFD4514S | Intervention Type: DRUG; Name: sham; Assigned to Arm(s): sham
B: Arm Label: Pegcetacoplan 15 mg/100 µL Monthly for 12 months; Type: EXPERIMENTAL; Interventions: Drug: Pegcetacoplan | Arm Label: Pegcetacoplan 15 mg/100 µL EOM for 12 months; Type: EXPERIMENTAL; Interventions: Drug: Pegcetacoplan | Arm Label: Sham Monthly for 12 months; Type: SHAM_COMPARATOR; Interventions: Other: Sham Procedure | Arm Label: Sham EOM for 12 months; Type: SHAM_COMPARATOR; Interventions: Other: Sham Procedure | Intervention Type: DRUG; Name: Pegcetacoplan; Assigned to Arm(s): Pegcetacoplan 15 mg/100 µL EOM for 12 months, Pegcetacoplan 15 mg/100 µL Monthly for 12 months | Intervention Type: OTHER; Name: Sham Procedure; Assigned to Arm(s): Sham EOM for 12 months, Sham Monthly for 12 months
C: Arm Label: Pegcetacoplan; Type: EXPERIMENTAL; Interventions: Drug: Pegcetacoplan, Drug: Soliris | Arm Label: Eculizumab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegcetacoplan, Drug: Soliris | Intervention Type: DRUG; Name: Pegcetacoplan; Assigned to Arm(s): Eculizumab, Pegcetacoplan | Intervention Type: DRUG; Name: Soliris; Assigned to Arm(s): Eculizumab, Pegcetacoplan
D: Arm Label: OT-551 antioxidant eye drop; Type: EXPERIMENTAL; Interventions: Drug: OT-551 antioxidant eye drop | Intervention Type: DRUG; Name: OT-551 antioxidant eye drop; Assigned to Arm(s): OT-551 antioxidant eye drop

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Pieda Study: A Phase 3b Investigation Of Erythropoietin Drugs Using A Specified Dosing Algorithm: A Randomized Open Label Dosing Study In Adult Chronic Kidney Disease Subjects On Hemodialysis
Brief Summary: A phase 3b study for subjects receiving Epogen to compare a dosing algorithm between Hospira Epoetin and Standard of Care Epogen.


Options:
A: Arm Label: Epoetin Hospira; Type: OTHER; Interventions: Biological: Epoetin Hospira Arm, Drug: IV Iron | Arm Label: Standard of Care; Type: OTHER; Interventions: Other: Standard of Care Arm, Drug: IV Iron | Intervention Type: BIOLOGICAL; Name: Epoetin Hospira Arm; Assigned to Arm(s): Epoetin Hospira | Intervention Type: OTHER; Name: Standard of Care Arm; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: IV Iron; Assigned to Arm(s): Epoetin Hospira, Standard of Care
B: Arm Label: High Hb group; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin alfa | Arm Label: Low Hb group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin alfa | Intervention Type: DRUG; Name: Darbepoetin alfa; Assigned to Arm(s): High Hb group, Low Hb group
C: Arm Label: Erythropoiesis Stimulating Agents; Type: ACTIVE_COMPARATOR; Interventions: Drug: Darbepoetin Alfa, Drug: Epoetin Alfa, Drug: Epoetin Beta, Drug: methoxy polyethylene glycol-epoetin beta | Arm Label: Methoxy Polyethylene Glycol-Epoetin Beta; Type: EXPERIMENTAL; Interventions: Drug: Darbepoetin Alfa, Drug: Epoetin Alfa, Drug: methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta | Intervention Type: DRUG; Name: Epoetin Beta; Assigned to Arm(s): Erythropoiesis Stimulating Agents | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Erythropoiesis Stimulating Agents, Methoxy Polyethylene Glycol-Epoetin Beta
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: darbepoetin alfa | Intervention Type: DRUG; Name: darbepoetin alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): 1

Answer: A